Candida spp. are the fourth leading cause of bloodstream infections. Mortality in candidaemia remains substantial. In recent years Candida non-albicans species are increasing. Inadequate and delayed antifungal treatment for candidaemia is associated with increased hospital mortality. While fluconazole has been shown to be safe and effective in Candida albicans, amphotericin B deoxycholate has substantial adverse events although being effective in most patients with candidaemia caused by non-albicans species. With the advent of new antifungals the efficacy and safety of antifungal treatment have been improved substantially. This review summarises the new treatment options in candidaemia.